FDA approves new indication for drug to treat pediatric NDO patients

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. FDA approves new indication for drug to treat pediatric NDO patients

Sealing fistulas more effectively with water-immiscible mussel protein-based bioadhesive

A Korean research team has recently developed an innovative vesico-vaginal fistula treatment method using the mussel adhesive protein (MAP) that can effectively seal fistulas in organs even when exposed to urine. Sealing fistulas more effectively with water-immiscible mussel protein-based bioadhesive

App-based treatment for urinary incontinence was as effective as in-person treatment

A mobile app designed to help women manage urinary incontinence was as effective as usual, in-person treatment of incontinence in primary care, according to new research from the Netherlands. App-based treatment for urinary incontinence was as effective as in-person treatment

App-based treatment for urinary incontinence was as effective as in-person treatment

A mobile app designed to help women manage urinary incontinence was as effective as usual, in-person treatment of incontinence in primary care, according to new research from the Netherlands. App-based treatment for urinary incontinence was as effective as in-person treatment